Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$4.80 – $8.95
88% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2M | $22.6M | $44.7M | $66.4M | $111.9M | $0 |
| Cost of revenue | $514.7K | $14.2M | $5.9M | $6.5M | $11.4M | $0 |
| Gross profit | $710.0K | $8.4M | $38.8M | $59.9M | $100.6M | $0 |
| Gross margin | 58.0% | 37.1% | 86.8% | 90.2% | 89.8% | — |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $1.4M | $937.1K | $33.7M | $24.1M | −$888.3K | $88.8M |
| EBITDA | $662.0K | $1.0M | $34.8M | $23.8M | $6.8M | $31.8M |
| Net income | $662.0K | $997.4K | $31.7M | $9.5M | −$24.0M | $36.5M |
| Net margin | 54.1% | 4.4% | 70.9% | 14.3% | -21.4% | — |
| EPS (diluted) | 0.03 | 0.02 | 0.63 | 0.16 | -0.34 | 0.38 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $260M | $1.00 | $0.86–$1.06 | 4 |
| 2027 | $288M | $1.13 | $0.99–$1.33 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds ABL.
No tracked institution reports a position in ABL as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2025-12-02 | $0.2000 | 2025-12-17 |
No one on the platform has traded ABL yet.
| -1.92% |
| $577M |
| — |
| EGBNEagle Bancorp, Inc. | $28.54 | -2.03% | $870M | — |
| HQLTekla Life Sciences Investors | $19.76 | +2.65% | $601M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.